Findings from a retrospective study by researchers from NYU suggest that women with COVID-19 in pregnancy have an increased risk of placental abnormalities, regardless of whether their infection is symptomatic.
If their data are confirmed in future studies, say the authors, long-term neonatal follow-up may be warranted in such patients.
Published in The American Journal of Obstetrics and Gynecology,1 the report is from a cohort of women admitted for delivery at ≥37 weeks between March 31, 2020 and June 17, 2020. Placental histopathological findings from 77 women with COVID-19 who delivered a singleton at term were compared to a control group of 56 term patients without COVID-19.
On admission, all of the patients had been tested for COVID-19. None of the controls had obstetrics or medical complications. Multivariable logistic regression models were created for variables that were significant in univariable analyses. A subgroup analysis also was performed to compared women with asymptomatic COVID-19 infection to the controls.
Women with COVID-19 were significantly more likely to be younger (29.9 years vs 32.2 years, P = 0.02), Hispanic (55.8% vs 17.6%, P = 0.01), and to deliver vaginally (74% vs 25%, P < 0.0001) compared to controls.
Of the patients studied, 87% were asymptomatic. In the remainder, any symptoms were mild and included fever, cough, upper respiratory complaints, and shortness of breath. No testing for inflammatory markers or coagulation studies were performed because they were not indicated.
Univariable analyses showed that the placentas of the women with COVID-19 were more likely to have evidence of fetal vascular malperfusion (32.5% vs 3.6%, P < 0.0001) and villitis of unknown etiology (20.8% vs 7.1%, P = 0.030). These findings persisted in a subgroup comparison of women with asymptomatic COVID-19 versus controls.
Frequency of fetal vascular malperfusion abnormalities remained significantly higher in the COVID-19 group (odds ratio [OR] = 12.63, 95% confidence interval [CI] 2.40-66.40) in a multivariable model that adjusted for maternal age, race/ethnicity, mode of delivery, pre-eclampsia, fetal growth restriction, and oligohydramnios.
Frequency of villitis of unknown etiology was more than double in the placentas of women with COVID-19 versus the controls, but the difference was not statistically significant in a multivariable model (OR = 2.11, 95% CI 0.50-8.97).
All of the infants born to COVID-19-positive mothers tested negative for SARS-CoV-2 on polymerase chain reaction.
Despite the increased rate of placental abnormalities in the COVID-19-positive mothers, their infants had birthweights, rates of neonatal intensive care unit admission, and APGAR scores similar to that in infants of mothers in the control group.
The authors hypothesized that “this suggests that the placenta may act as a defensive biological ‘filter,’ offering a degree of protection to the neonate, may modify its immune status or may actively produce factors that may protect the fetus in utero.”
They underscored, however, that there may still be “injury” to the placenta, and noted that the possibility of adverse effects in the neonates points to a need for follow-up in these cases for long-term side effects.
__
Reference
Rising endometriosis rates linked to increased pregnancy complications
May 19th 2024A new study presented at the 2024 ACOG meeting reveals a significant rise in endometriosis among pregnant women over the past 20 years, linking the condition to increased obstetric and neonatal complications.
Read More
S4E1: New RNA platform can predict pregnancy complications
February 11th 2022In this episode of Pap Talk, Contemporary OB/GYN® sat down with Maneesh Jain, CEO of Mirvie, and Michal Elovitz, MD, chief medical advisor at Mirvie, a new RNA platform that is able to predict pregnancy complications by revealing the biology of each pregnancy. They discussed recently published data regarding the platform's ability to predict preeclampsia and preterm birth.
Listen
Impact of antiepileptic medications and sex hormones on maternal and child outcomes in epilepsy
May 16th 2024Paula Emanuela Voinescu, MD, PhD, director of the Women's Epilepsy Program at Brigham and Women's Hospital, talked about the influence of sex hormones on maternal outcomes in pregnant women with epilepsy treated with antiseizure medication.
Read More
Contemporary OB/GYN Senior Editor Angie DeRosa gets insight on the current state of COVID-19 from Christina Han, MD, division director of maternal-fetal medicine at the University of California, Los Angeles, and member of its COVID-19 task force. Han is an active member of the Society for Maternal-Fetal Medicine and discusses the issues on behalf of SMFM.
Listen
Echogenic Mass identified as key predictor for retained products of conception
May 13th 2024Discover how recent findings highlight the significance of echogenic masses in accurately diagnosing post-pregnancy complications, shedding light on effective management strategies and reducing the need for invasive interventions.
Read More